Towa International makes its CMO/CDMO model official
Barcelona, June 21, 2024. Towa International, an international pharmaceutical holding company specialized in the research, development, manufacture, marketing and distribution of generic and value-added medicines, which distributes directly in Europe and the United States through its commercial subsidiaries, Towa Pharmaceutical and Breckenridge Pharmaceutical, and in more than 30 countries through its Towa2B business unit, has announced the launch of a new business line: CMO/CDMO at its Martorelles plant (Barcelona). The main objective of this launch is to offer its production and/or R&D potential to other generic and/or innovative companies in the pharmaceutical sector to develop and manufacture their medicines.
«By formalizing this new business model, we take full advantage of our state-of-the-art infrastructure and our extensive experience and expertise in medicine development and production. Our CMO/CDMO service allows us to position ourselves as a trusted partner for companies looking to outsource their development and production efficiently and safely,» explains David Peix, CEO of Towa International.
Oscar Pi, CCO of Towa2B – the division that encompasses this new activity – adds: «This new business model underlines our commitment to being a key partner in the pharmaceutical industry with the aim of meeting the needs of our customers in order to reach the greatest number of patients and contribute to people’s health».
Since its creation four years ago, Towa International has invested more than 20 million euros to increase its production capacity in various areas. In particular, a significant improvement is being made to be able to develop complex medicines in the oncology area. In addition, it has increased specialized technology in the pellet area where the company is a leading manufacturer in Europe, enabling it to become a European leader in controlled-release products.
More than 35,000m2 of facilities in Barcelona
With more than 35,000 m2 of facilities and equipped with state-of-the-art technology, the Martorelles plant is one of the largest in Europe. Its high production capacity, equivalent to more than 5.6 billion doses per year, continues to increase year after year.
Towa International’s excellence goes beyond production. In the last two years, the company’s R&D center and pilot plant in Martorelles have acquired a fundamental role, becoming the center of excellence for the company’s parent company, Towa Pharmaceutical. A milestone that consolidates the company’s leading position worldwide and highlights its commitment to innovation and continuous development. In addition, last February, Towa obtained PMDA certification from the Japanese authorities, in addition to the FDA, EMA and SFDA.
Virtual Tour: Towa International opens its doors to the world
For the first time, the company has opened the doors of its production plant and pilot plant through a Virtual Tour that allows users to tour the facilities and obtain information on each of the areas. This project was created with the aim of facilitating access to the company’s information, while maintaining its highest commitment to transparency.
Specifically, this interactive experience offers a complete overview of the drug development and manufacturing process, covering the different areas, from pellet production, through the bulk solids area, packaging, warehouse, culminating in the laboratory and pilot plant.
The Towa International Virtual Tour is available in English and Spanish on the company’s website and through this link.
